Roux-en-Y胃旁路手术治疗家族性部分性脂肪营养不良1型
本文报告了三例对药物治疗抵抗的家族性部分性脂肪营养不良1型(FPLD1)患者接受Roux-en-Y胃旁路术(RYGB)后的代谢反应。RYGB与体重下降、血糖控制和胰岛素敏感性显著改善相关,所有三例患者均停用胰岛素。作者认为,对于部分性脂肪营养不良合并难治性代谢疾病的患者,应考虑RYGB。
要点
- RYGB使三例FPLD1患者体重下降,血糖控制和胰岛素敏感性显著改善。
- 所有三例患者术后均停用胰岛素。
- 其中两例患者体重指数低于30 kg/m2。
核心结论
- RYGB手术使三例FPLD1患者的血糖控制显著改善,其中两例体重指数低于30 kg/m2。
- 作者认为,对于部分性脂肪营养不良合并难治性代谢疾病的患者,应考虑RYGB。
研究设计与样本
- 本文详细描述了三例对药物治疗抵抗的FPLD1患者接受胃旁路手术后的代谢反应。
主要发现
- RYGB与体重下降以及血糖控制和胰岛素敏感性的显著改善相关。
- 所有三例患者均能够停用胰岛素。
- 一例患者的葡萄糖耐量试验显示术后L细胞来源的肠道激素反应增加。
临床怎么用
- 作者认为,对于部分性脂肪营养不良合并难治性代谢疾病的患者,应考虑RYGB。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Familial partial lipodystrophy type 1 (FPLD1) is an extreme form of central adiposity, with peripheral lipodystrophy associated with severe manifestations of the metabolic syndrome, often poorly responsive to standard therapeutic approaches. Body mass index in FPLD1 varies but, in many cases, is below the level at which metabolic surgery is usually considered as a therapeutic option. DESIGN: We detailed the metabolic response to gastric bypass surgery of three patients with FPLD1, refractory to medical therapy. RESULTS: Roux-en-Y gastric bypass (RYGB) was associated with weight loss and substantial improvements in glycemic control and insulin sensitivity. All three patients were able to stop using insulin. Glucose tolerance testing in one patient demonstrated an increase in L-cell-derived gut hormone responses postoperatively. CONCLUSION: RYGB surgery substantially improved glycemic control in three patients with FPLD1, two of whom had body mass indices below 30 kg/m2. RYGB should be considered in patients with partial lipodystrophy and refractory metabolic disease.
引用
- Melvin A, Adams C, Flanagan C, et al. Roux-en-Y Gastric Bypass Surgery in the Management of Familial Partial Lipodystrophy Type 1. J Clin Endocrinol Metab. 2017. PMID: 28973478. doi:10.1210/jc.2017-01235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。